

EN
E-004254/2025
Answer given by Mr Várhelyi
on behalf of the European Commission
(23.1.2026)

The European Medicines Agency considers the totality of safety data when monitoring the safety of COVID-19 vaccines, including the medical literature. This specific study, and other relevant studies, are reviewed as part of the continuous safety monitoring of all approved medicines. At this time, there has been no confirmed signal of cancer following COVID-19 vaccination.

Causes of cancer are multifactorial, with established risk factors including, among others, smoking, obesity, ultraviolet radiation, alcohol, diet, infections including human papillomavirus (HPV), pollution, hormones, age, and genetic predisposition.

Accounting for all the relevant risk factors already present in the general population and the lag time between exposure to any of these risk factors and a cancer diagnosis poses significant methodological challenges for studies aiming to link cancer to specific causes.

The European Medicines Agency and Member States continue to monitor all evidence on the safety of COVID-19 vaccines and investigate any possible causal link with vaccinations as part of the continuous monitoring. If a risk is identified, it will be included in the vaccine's product information and the Commission will take any necessary regulatory action as needed, including to ensure appropriate communication by the European Medicines Agency to healthcare professionals and patients.

It is noteworthy that a recent study published in Nature, showed that on the contrary, mRNA COVID-19 vaccination improved survival of patients that were treated with specific anticancer medicines¹.

¹ SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
<https://www.nature.com/articles/s41586-025-09655-y>.